Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists.
The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target programmed death receptor-1 (PD-1) will block the ligand-receptor interface, thereby allowing T cells to attack the tumor and increase antitumor imm...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 140; no. 4; pp. 341 - 345 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Apr2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114257306&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 114257306 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Apr2016 vid: 140 iid: 4 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 114257306 114257306 114257306 10.5858/arpa.2015-0506-SA 114257306 ppf: 341 ppct: 4 formats: fmt: @attributes: type: P tig: atl: Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists. aug: au: Sholl, Lynette M. Aisner, Dara L. Craig Allen, Timothy Beasley, Mary Beth Borczuk, Alain C. Cagle, Philip T. Capelozzi, Vera Dacic, Sanja Hariri, Lida Kerr, Keith M. Lantuejoul, Sylvie Mino-Kenudson, Mari Raparia, Kirtee Rekhtman, Natasha Roy-Chowdhuri, Sinchita Thunnissen, Eric Ming Sound Tsao Yasushi Yatabe affil: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts sug: subj: Immunohistochemistry Membrane Proteins Analysis Carcinoma, Non-Small-Cell Lung Pathology Carcinoma, Non-Small-Cell Lung Drug Therapy Immunotherapy Pathology Organizations Immunohistochemistry Equipment and Supplies Membrane Proteins Antagonists and Inhibitors Antibodies, Monoclonal Therapeutic Use ab: The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target programmed death receptor-1 (PD-1) will block the ligand-receptor interface, thereby allowing T cells to attack the tumor and increase antitumor immune response. In clinical trials, PD-1 inhibitors have been associated with an approximately 20% overall response rate in unselected patients with non-small cell lung cancer, with sustained tumor response in a subset of patients treated by these immune checkpoint inhibitors. Facing a proliferation of PD-L1 immunohistochemistry clones, staining platforms, and scoring criteria, the pathologist must decide on the feasibility of introducing a newly approved companion diagnostic assay that may require purchase not only of a specific antibody kit but of a particular staining platform. Given the likely reality that clinical practice may, in the near future, demand access to 4 different PD-L1 antibodies coupled with different immunohistochemistry platforms, laboratories will be challenged with deciding among this variety of testing methods, each with its own potential benefits. Another immediate challenge to PD-L1 testing in lung cancer patients is that of access to adequate tumor tissue, given that non-small cell lung cancer samples are often extremely limited in size. With PD-L1 testing it has become clear that the historically used US regulatory approach of one assay-one drug will not be sustainable. One evolving concept is that of complementary diagnostics, a novel regulatory pathway initiated by the US Food and Drug Administration, which is distinct from companion diagnostics in that it may present additional flexibility. Although pathologists need to face the practical reality that oncologists will be asking regularly for the PD-L1 immunohistochemistry status of their patients' tumors, we should also keep in mind that there may be room for improvement of biomarkers for immunotherapy response. The field is rich with opportunities for investigation into biomarkers of immunotherapy response, particularly in the form of collaborative, multidisciplinary studies that incorporate oncologists, pathologists, and basic scientists. Pathologists must take the lead in the rational incorporation of these biomarkers into clinical practice. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|